Halda Therapeutics is being sold to Johnson & Johnson for $3.05 billion.

Halda Therapeutics announced today that it has signed a definitive agreement for an acquisition by Johnson & Johnson for $3.05 billion in cash. The closing of the transaction is subject to customary adjustments.

Halda has achieved positive results in metastatic castration-resistant prostate cancer (mCRPC) with its developed therapeutic HLD-0915. Recently presented Phase 1/2 data indicated that this innovative treatment is well tolerated and has shown positive responses against tumor activity with reductions in prostate-specific antigen (PSA) levels. These results were obtained in patients who had previously undergone many treatment trials and exhausted existing therapies.

Halda's CEO, Christian S. Schade, stated, "Halda's goal is to develop the next generation of selective and proximity-based small molecule therapies for patients with serious diseases. With this agreement, we will continue to rapidly advance our promising program for prostate cancer."

The agreement is expected to close in the coming months after the expiration of the necessary waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. During this process, Johnson & Johnson and Halda will continue to operate as separate and independent companies.

Halda is a clinical-stage biotechnology company that has developed the advanced RIPTAC™ (Regulated Proximity Targeting Chimera) module for the precise treatment of cancer and other diseases. This mechanism is designed to overcome the cancer's ability to evolve resistance mechanisms. Halda is located in New Haven, Connecticut and was founded in 2019.